Mark Vaeck News Today

Alphabodies cross over the boundaries between biologics and small chemical drugs Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments w

Half a century ago, the first genetically modified organism ushered in a new era of biological innovation. To mark this anniversary, here are eight milestone GMOs. Many have had, or are poised to have, a dramatic impact on our lives.

MyNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccineCAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer GHENT, Belgium – October 25th 2023. myNEO, a biotech company focused on exploiting “d...

myNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark...

Since the first genetically modified organism 50 years ago, GMOs have brought us disease-resistant crops, new drugs and more.

Issuer: CureVac / Key word(s): Alliance25.05.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development CureVac is broadening its foundation in oncology, leveraging recent progress with it...

Issuer: CureVac / Key word(s): Alliance CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine ...

CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backboneThe partnership combines CureVac's mRNA technology with myNEO's platform for the discovery

DGAP-News: CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member